Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference
May 18 2023 - 07:05AM
Business Wire
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of seralutinib for the treatment of pulmonary
arterial hypertension (PAH), today announced data from its Phase 2
TORREY Study of seralutinib in patients with PAH will be featured
in two sessions at the American Thoracic Society 2023 International
Conference taking place in Washington D.C. from May 19-24. Dr.
Robert Frantz, Director of the Pulmonary Hypertension Clinic and
Professor of Medicine at Mayo Clinic will present the data on
behalf of the TORREY Study investigators.
Session and Poster Details
Session Title: Breaking News: 2023 Clinical Trial Results
in Pulmonary Medicine Date and Time: Monday, May 22, 2023,
9:04 AM EDT Session Location: Walter E. Washington
Convention Center, Ballroom C (Level 3) Presentation Title:
Seralutinib Treatment in Adult Subjects with Pulmonary Arterial
Hypertension: Results from the TORREY Study Presenting
Author: Robert Frantz, M.D.
Session Title: Poster Discussion Session. D106. HOT OFF
THE PRESSES! LATE BREAKERS IN PULMONARY VASCULAR DISEASE Date
and Time: Wednesday, May 24, 2023, 12:00 PM EDT Session
Location: Walter E. Washington Convention Center, Room 151 A
(Street Level) Poster Title: 401 - Seralutinib for the
Treatment of Pulmonary Arterial Hypertension (PAH): Results From
the Phase 2 TORREY Trial Presenting Author: Robert Frantz,
M.D.
The presentation and poster will also be made available in the
“Posters and Publications” section of the Gossamer Bio website at
gossamerbio.com.
Following the positive results observed in the TORREY study and
discussions with worldwide regulatory authorities, Gossamer plans
to initiate a registrational Phase 3 clinical trial in patients
with PAH in the third quarter of 2023.
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company
focused on the development and commercialization of seralutinib for
the treatment of pulmonary arterial hypertension. Its goal is to be
an industry leader in, and to enhance the lives of patients
suffering from, pulmonary hypertension.
Forward-Looking Statements
Gossamer cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. These statements are based on the
Company’s current beliefs and expectations. Such forward-looking
statements include, but are not limited to, statements regarding:
the anticipated timing of initiation and enrollment of clinical
trials for seralutinib, including the expected initiation of a
Phase 3 clinical program for seralutinib. The inclusion of
forward-looking statements should not be regarded as a
representation by Gossamer that any of its plans will be achieved.
Actual results may differ from those set forth in this press
release due to the risks and uncertainties inherent in Gossamer’s
business, including, without limitation: potential delays in the
commencement, enrollment and completion of clinical trials; later
developments with and / or feedback from global regulatory
authorities or the FDA that may differ from prior feedback which
may alter our planned Phase 3 clinical trial design and timing of
initiation thereof; disruption to our operations from the COVID-19
pandemic, including clinical trial delays; the Company’s dependence
on third parties in connection with product manufacturing, research
and preclinical and clinical testing; the results of preclinical
studies and early clinical trials are not necessarily predictive of
future results; the success of Gossamer’s clinical trials and
preclinical studies for seralutinib; regulatory developments in the
United States and foreign countries; unexpected adverse side
effects or inadequate efficacy of seralutinib that may limit their
development, regulatory approval and/or commercialization, or may
result in clinical holds, recalls or product liability claims;
Gossamer’s ability to obtain and maintain intellectual property
protection for seralutinib; Gossamer’s ability to comply with its
obligations in collaboration agreements with third parties or the
agreements under which it licenses intellectual property rights
from third parties; unstable market and economic conditions and
adverse developments with respect to financial institutions and
associated liquidity risk may adversely affect our business and
financial condition and the broader economy and biotechnology
industry; Gossamer may use its capital resources sooner than it
expects; and other risks described in the Company’s prior press
releases and the Company’s filings with the Securities and Exchange
Commission (SEC), including under the heading “Risk Factors” in the
Company’s annual report on Form 10-K and any subsequent filings
with the SEC. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and Gossamer undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date hereof. All forward-looking statements are qualified
in their entirety by this cautionary statement, which is made under
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230518005332/en/
For Investors and Media: Bryan Giraudo, Chief Operating
Officer and Chief Financial Officer Gossamer Bio Investor Relations
ir@gossamerbio.com
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Nov 2023 to Dec 2023
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Dec 2022 to Dec 2023